At a glance
ClinicalIndex Comparison RecordPhase 2Active· 35 target
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05078931Phase 2ActiveUpdate OverdueUpdated 11mo ago · Completion was 6mo agoEnrollment Stalled
An Open-label, Single-arm Phase II Study of Pembrolizumab Plus Lenvatinib in PD-L1 Positive Patients With TKI-resistant EGFR-mutated Advanced Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Lenvatinib for NSCLC. Active but no longer recruiting, targeting 35 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
This study will investigate the efficacy and safety of the combination of pembrolizumab and lenvatinib in PD-L1 positive patients with TKI-resistant EGFR-mutated advanced NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC
CountriesChina
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2Active
202220232024202520262027
First PostedOct 2021
Enrollment StartOct 2021
Primary CompletionDec 2025
TodayJul 2026
Study CompletionDec 2026
First PostedOct 15, 2021
Enrollment StartOct 27, 2021
Primary CompletionDec 30, 2025
Study CompletionDec 30, 2026
TodayJul 1, 2026
Enrollment to primary: 4.2 yearsPosted 4.7 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks for up to 35 cycles
Lenvatinibdrug
Lenvatinib 20mg will be administered orally daily.